Skip to Main Content

The (POGO) Blog

August 17, 2017

By Laura Peterson

Lawmakers Question Interior Secretary Over Whistleblower Reassignment



Joel Clement Members of Congress are supporting a Department of Interior executive who says management retaliated against him because he disclosed how climate change is putting Alaskan coastal communities at risk.

Continue Reading Lawmakers Question Interior Secretary Over Whistleblower Reassignment

Topics: Whistleblower Protections, Energy and Natural Resources, Public Health and Science

April 3, 2017

By David S. Hilzenrath

Questions for Trump’s FDA Nominee



Scott Gottlieb President Donald Trump’s nominee to head the Food and Drug Administration has deep roots in the pharmaceutical industry he would oversee.

Continue Reading Questions for Trump’s FDA Nominee

Topics: Public Health and Science

March 28, 2017

By Ari Goldberg

POGO's 2017 Baker’s Dozen Wishlist for Congress



Aerial U.S. Capitol Building The Project On Government Oversight (POGO) has unveiled its biennial list of 13 policy areas ripe for Congressional action. It includes recommendations for legislative fixes to make the federal government more transparent, accountable, and ethical.

Continue Reading POGO's 2017 Baker’s Dozen Wishlist for Congress

Topics: Government Accountability, Open Government, Whistleblower Protections, Energy and Natural Resources, National Security, Public Health and Science, Contract Oversight

March 3, 2017

By David S. Hilzenrath

Trump’s Dangerous Prescription for the FDA



President Trump addressing a joint session of Congress, with VP Mike Pence and Rep. Paul Ryan seated behind him, clapping. President Donald Trump called the FDA drug approval process slow and burdensome, but the evidence he cited could point to the opposite conclusion. Slashing regulatory restraints as he proposed could pose medical and financial hazards.

Continue Reading Trump’s Dangerous Prescription for the FDA

Topics: Government Accountability, Open Government, Public Health and Science

February 22, 2017

By Ned Feder, M.D.

Let There Be Light: The FDA's Surprising New Policy



FDA Shrouded in Darkness - the Food and Drug Administration building and sign The Food and Drug Administration has a brand-new policy bringing greater transparency regarding the agency's advisory committee members. The increased transparency will help address concerns over these members' conflicts of interest and the advice they giv

Continue Reading Let There Be Light: The FDA's Surprising New Policy

Topics: Government Accountability, Open Government, Public Health and Science

Items 1 - 5 of 51  12345678910Next

Browse POGOBlog by Topic

POGO on Facebook